

Spinal Muscular Atrophy (SMA)

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Trial Status
Recruiting

Trial Runs In
4 Countries

Trial Identifier
NCT05861999 2023-505161-81-00
BN44621

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children <2 years of age genetically diagnosed with SMA.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT05861999 2023-505161-81-00 BN44621
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=3 Months & <= 24 Months

Healthy Volunteers
No
